Genomic-based targeted therapy and management of advanced non-small cell lung cancer: Protocol for a qualitative study of oncologists' perceptions and behaviors regarding genomic-based targeted therapy

Chen GJ, Arney J, Helm AM, Braun U, Richardson P, Chen P, Hayes TG. Genomic-based targeted therapy and management of advanced non-small cell lung cancer: Protocol for a qualitative study of oncologists' perceptions and behaviors regarding genomic-based targeted therapy. Journal of solid tumors. 2015 Apr 1; 5(1):doi: 10.5430/jst.v5n1p33.

Related HSR&D Project(s)

• IIR 12-115 – Value of Delivery of Targeted Therapy for Veterans with Advanced Lung Cancer

Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.

If you have VA-Intranet access, click here for more information vaww.hsrd.research.va.gov/dimensions/

VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address.    Search Dimensions for VA for this citation
* Don't have VA-internal network access or a VA email address? Try searching the free-to-the-public version of Dimensions

Search for Abstract from PubMed

---

Abstract:

Background: Pilot data revealed gaps in knowledge and utilization of genomic-based targeted therapy among oncologists. We report these findings, and offer a protocol for a qualitative research project aimed to elicit oncologists' perceptions regarding use of genomic-based targeted therapy for Veterans with lung cancer at the VHA. Using the Cabana et al. theoretical framework, a model of behavior change among providers, the study will identify how oncologists' perceptions and facility characteristics potentially affect implementation of genomic-based targeted therapy in routine care. Methods and results: We will conduct a minimum of 40 and up to 60 semi-structured interviews with oncologists to elicit perceptions of genomic-based targeted therapy in four domains: 1) knowledge; 2) attitudes; 3) intent; and 4) barriers and facilitators for practicing genomic-based targeted therapy. Conclusion: This study is the first to examine decision-making surrounding the use of genomic based targeted therapy in lung cancer management. Findings will lay the foundation to design and implement effective strategies centering on integrating genomic medicine with routine practice, and will shed light on the decision-making processes of oncologists regarding selection of genomic-based and non-genomic-based treatment plans in managing lung cancer in veterans. This research is part of a larger study that will examine the utilization, clinical effectiveness, and cost effectiveness of genomic-based therapies in the treatment of advanced lung cancer.